Overview
This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)
Description
Primary Objective:
- To demonstrate that 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can detect additional cancers over mpMRI.
- To demonstrate that 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can assess changes in response to treatment and predict progression free survival (PFS) at 24 months.
Eligibility
Inclusion Criteria:
- Patients must be at least 18 years of age;
- Patients must be able to provide informed consent;
- Histologically proven low-grade or intermediate-grade prostate cancer (PC)
- Scheduled to undergo targeted local therapy (HDR brachytherapy).
Exclusion Criteria:
- Inability to lie still for the entire imaging time;
- Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.);
- Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance;
- Metallic implants (contraindicated for MRI).